<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Approach to refractory gastroesophageal reflux disease in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Approach to refractory gastroesophageal reflux disease in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Approach to refractory gastroesophageal reflux disease in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronnie Fass, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Talley, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite treatment with proton pump inhibitors (PPIs), some patients with gastroesophageal reflux disease (GERD) continue to have reflux symptoms or endoscopic evidence of esophagitis. This topic will review an approach to patients with refractory GERD. The clinical manifestations, diagnosis, and initial medical management of GERD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definition of refractory gastroesophageal reflux disease (GERD) is controversial [
         <a href="#rid1">
          1
         </a>
         ]. According to most experts, patients with GERD who exhibit partial or lack of response to proton pump inhibitor (PPI) twice daily are considered to have failed PPI therapy [
         <a href="#rid2">
          2
         </a>
         ]. GERD in these patients is termed refractory GERD. However, we suggest that lack of satisfactory symptomatic response to PPI once a day should be considered a failure of PPI therapy.
        </p>
        <p class="headingAnchor" id="H360019636">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 10 and 40 percent of patients with gastroesophageal reflux disease (GERD) fail to respond symptomatically, either partially or completely, to proton pump inhibitors (PPIs) [
         <a href="#rid3">
          3-6
         </a>
         ]. Most patients with GERD who do not respond to a PPI have either nonerosive reflux (NERD) or functional heartburn. In patients with NERD, the pooled symptomatic response rate to PPI once daily at four weeks is 37 percent [
         <a href="#rid7">
          7,8
         </a>
         ]. In contrast, in patients with erosive esophagitis, which accounts for 30 to 40 percent of the GERD population, the pooled symptomatic response rate is 56 percent [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ETIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2144070968">
         <span class="h2">
          Insufficient acid suppression
         </span>
         <span class="headingEndMark">
          —
         </span>
         A range of mechanisms can result in insufficient suppression of gastric acid.
        </p>
        <p class="headingAnchor" id="H238683443">
         <span class="h3">
          Medication related factors
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h4">
          Medication timing and adherence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Poor compliance with proton pump inhibitor (PPI) timing and adherence is an important cause for inadequate acid suppression and refractory GERD [
         <a href="#rid9">
          9-11
         </a>
         ]. PPIs should be administered 30 to 60 minutes before breakfast for maximal inhibition of proton pumps. In one study that included 100 patients with GERD, only 46 percent of patients prescribed a PPI for GERD were taking it as advised [
         <a href="#rid12">
          12,13
         </a>
         ]. Administration of PPIs before a meal provides better control of intragastric pH as compared with administration during or after a meal [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Dose and timing of administration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3277810384">
         <span class="h4">
          Differences in PPI metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs are metabolized through the hepatic cytochrome system, with CYP2C19 having the dominant role. The activity of CYP2C19 is determined to some extent by a genetic polymorphism. Approximately 5 percent of White patients and &gt;10 percent of Asian patients are homozygous for a
         <em>
          CYP2C19
         </em>
         mutation (ie, slow metabolizers), potentially leading to greater suppression of gastric acidity. However, in wild type homozygotes (rapid metabolizers) the effect of PPIs on gastric acidity is diminished and may contribute to PPI failure. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1650707089">
         <span class="h3">
          Residual acid reflux
         </span>
         <span class="headingEndMark">
          —
         </span>
         Residual acid reflux has been documented in patients despite PPI therapy, however, the incidence in patients on twice daily therapy is low [
         <a href="#rid15">
          15-19
         </a>
         ]. As an example, in one retrospective review of pH testing results in 135 GERD subjects with refractory symptoms on once or twice daily PPI therapy, results were abnormal in 31 and 4 percent, respectively [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         The presence of concentrated, highly acidic gastric juice postprandially at the gastroesophageal junction, termed the acid pocket, likely has a limited role in refractory GERD by causing re-reflux of gastric acid. A study that included 18 patients with GERD, of whom nine had a partial response to PPIs, demonstrated no difference in the pH or position of the acid pocket between PPI responders and nonresponders [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">
          "Pathophysiology of reflux esophagitis", section on 'Impaired esophageal acid clearance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H561996044">
         <span class="h3">
          Weakly acidic or alkaline reflux (non-acid reflux)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-acid reflux episodes primarily occur in the postprandial period as transient lower esophageal sphincter relaxation occurs more frequently following meal-induced gastric fundus distension. In patients on PPIs, treatment changes the acidity of the refluxate but does not decrease the volume of reflux or affect structural and motility abnormalities at the gastroesophageal junction responsible for GERD. In patients not on acid suppressive therapy, non-acid reflux results when gastric acid is buffered by the ingested food in the postprandial period. The clinical manifestations, diagnosis, and management of non-acid reflux is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">
          "Pathophysiology of reflux esophagitis", section on 'Anatomic disruption of the gastroesophageal junction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2244.html" rel="external">
          "Non-acid reflux: Clinical manifestations, diagnosis, and management", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H628372119">
         <span class="h2">
          Reflux hypersensitivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reflux hypersensitivity is characterized by retrosternal symptoms, including heartburn and chest pain associated with non-pathologic acid exposure [
         <a href="#rid22">
          22
         </a>
         ]. In patients with esophageal hypersensitivity, proximal migration of weakly acidic reflux and the presence of gas in the refluxate are pivotal for symptom generation [
         <a href="#rid21">
          21,23
         </a>
         ].
        </p>
        <p>
         There are limited data on the prevalence of reflux hypersensitivity [
         <a href="#rid24">
          24,25
         </a>
         ]. In a study of 329 patients with non-erosive reflux disease who underwent pH–impedance monitoring, 40 percent had abnormal acid exposure. The prevalence of reflux hypersensitivity and functional heartburn were 36 and 24 percent, respectively [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         According to the Rome IV criteria, a diagnosis of reflux hypersensitivity requires all of the following criteria be fulfilled for the last three months with symptom onset at least six months prior to the diagnosis [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retrosternal symptoms including heartburn or chest pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal endoscopy and absence of evidence that eosinophilic esophagitis is the cause for symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of major esophageal motor disorders (achalasia/esophagogastric junction outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, absent peristalsis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of triggering of symptoms by reflux events despite normal acid exposure on pH or pH–impedance monitoring (response to antisecretory therapy does not exclude the diagnosis)
        </p>
        <p>
        </p>
        <p>
         Esophageal hypersensitivity is analogous to the visceral hyperalgesia described in other functional gastrointestinal disorders (eg, functional chest pain, functional dyspepsia) and is driven by similar mechanisms of altered central processing of visceral stimuli, altered autonomic activity, and psychological abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/2262.html" rel="external">
          "Evaluation of the adult with chest pain of esophageal origin"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/19.html" rel="external">
          "Functional dyspepsia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2548862674">
         <span class="h2">
          Functional heartburn
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional heartburn is among the most common cause for failure of PPI treatment. It is estimated that up to 58 percent of patients with persistent heartburn despite PPI therapy have functional heartburn [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
         According to the Rome IV criteria, a diagnosis of functional heartburn requires all of the following criteria be fulfilled for the last three months with symptom onset at least six months prior to the diagnosis [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Burning retrosternal discomfort or pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of symptom relief despite optimal antisecretory therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of evidence that gastroesophageal reflux (abnormal acid exposure and symptom reflux association) or eosinophilic esophagitis are the cause of symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of major esophageal motor disorders (achalasia/esophagogastric junction outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, absent peristalsis)
        </p>
        <p>
        </p>
        <p>
         Most patients with functional heartburn have chronic symptoms that vary in severity over time. In one study that included 40 patients with functional heartburn, 22 months after initial testing, 66 percent of patients remained symptomatic [
         <a href="#rid27">
          27
         </a>
         ]. The underlying mechanisms responsible for symptoms in functional heartburn remain to be elucidated. Increased esophageal sensitivity to chemical, mechanical, and electrical stimuli in this patient population has not been consistently demonstrated [
         <a href="#rid28">
          28-31
         </a>
         ]. Psychological co-morbidities may provide an explanation for functional heartburn [
         <a href="#rid32">
          32
         </a>
         ]. Patients with poor correlation of symptoms with acid reflux events display a high level of anxiety as compared with patients who demonstrate a close correlation between symptoms and acid reflux events [
         <a href="#rid33">
          33
         </a>
         ]. In population-based studies, anxiety and depression have been also been demonstrated to increase GERD-related symptoms [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H490761683">
         <span class="h2">
          Alternative diagnoses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other diseases that can mimic symptoms of GERD include achalasia, eosinophilic esophagitis, infectious esophagitis, pill esophagitis, gastroparesis, and rarely esophageal stricture or cancer. Rumination syndrome may also be misdiagnosed as GERD. Refractory GERD can be distinguished from these conditions by diagnostic testing. Patients with functional dyspepsia commonly also complain of heartburn which may be misdiagnosed as refractory GERD [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Diagnostic testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting", section on 'Rumination syndrome'
         </a>
         .)
        </p>
        <p>
         Bile reflux may have a role in a subset of patients with difficult to manage symptomatic reflux. In a study that included 65 patients with persistent heartburn and regurgitation while on single-dose PPI therapy, seven patients (11 percent) had only pathological acid exposure, 25 (38 percent) had only pathological bile exposure, and 17 (26 percent) had pathological exposure to both acid and bile [
         <a href="#rid36">
          36
         </a>
         ]. Furthermore, in a carefully selected group of patients with symptoms refractory to PPI therapy,
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         significantly reduced bile reflux exposure and heartburn. Although these studies suggest a role for measurement of bile reflux in patients with persistent reflux symptoms despite PPI therapy, bile reflux monitoring is not widely available. (See
         <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">
          "Pathophysiology of reflux esophagitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2244.html" rel="external">
          "Non-acid reflux: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          INITIAL ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compliance with proton pump inhibitors (PPI) therapy and specifically, timing in relation to meals, should be sought. Patients with continued symptoms should be carefully reassessed, paying specific attention to the type of ongoing symptoms, and the degree to which symptoms have improved or worsened. It is important to recognize that complete relief of heartburn with PPIs occurs at a rate of approximately 11.5 percent per week [
         <a href="#rid37">
          37
         </a>
         ]. Thus, endoscopic healing and symptom relief are achieved within eight weeks in the majority of patients. However, patients with severe esophagitis (eg, Los Angeles C or D esophagitis) may take longer to heal. (See
         <a class="local">
          'Medication timing and adherence'
         </a>
         above.)
        </p>
        <p>
         In addition, we perform blood count to identify patients with iron deficiency anemia, if not recently performed. (See
         <a class="local">
          'Alarm features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2210531231">
         <span class="h1">
          DIAGNOSTIC STRATEGIES AND INITIAL MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing and extent of diagnostic evaluation in a patient with refractory gastroesophageal reflux disease (GERD) is based on the type of ongoing symptoms and the presence of alarm features. A suggested approach to the management of patients who have failed once daily proton pump inhibitors (PPI) therapy is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef70106" data-inline-graphics="70106" href="/z/d/graphic/70106.html" rel="external">
          algorithm 1
         </a>
         ).
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120419">
          (Related Pathway(s):
          <a class="utd-content-120419" href="/pathway/120419?topicRef=2239&amp;source=see_link">
           Gastroesophageal reflux disease: Identification of adults who require upper endoscopy
          </a>
          .)
         </span>
        </p>
        <p class="headingAnchor" id="H3324609889">
         <span class="h2">
          Alarm features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alarm features that may be suggestive of a gastrointestinal malignancy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New onset dyspepsia in patient ≥60 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of gastrointestinal bleeding (hematemesis, melena, hematochezia, occult blood in stool)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iron deficiency anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anorexia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained weight loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysphagia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Odynophagia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent vomiting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal cancer in a first-degree relative
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1186639745">
         <span class="h2">
          Patients with alarm features
         </span>
        </p>
        <p class="headingAnchor" id="H2731327913">
         <span class="h3">
          Early upper endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An early upper endoscopy (within two weeks) should be performed for the evaluation of new alarm features to determine the underlying etiology. Upper endoscopy should not be delayed pending a trial of empiric therapy in patients with alarm symptoms. In patients who have previously undergone an upper endoscopy, we perform a repeat upper endoscopy if new alarm features developed since the last upper endoscopy was performed. Biopsies of the esophagus should be obtained to rule out eosinophilic esophagitis. (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         In patients with a normal upper endoscopy, additional evaluation may be required based on symptoms (eg, abdominal imaging in patients with concurrent weight loss). If this evaluation is normal and symptoms of GERD persist, patients should be managed similarly to patients without alarm features. (See
         <a class="local">
          'Patients without alarm features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H894860270">
         <span class="h2">
          Patients without alarm features
         </span>
        </p>
        <p class="headingAnchor" id="H3029283604">
         <span class="h3">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifestyle and dietary modification, and compliance with PPI therapy should be reinforced. Patients should be instructed to take a PPI 30 minutes before a meal. Lifestyle and dietary modification include avoidance of identified dietary triggers, weight loss for patients who are overweight or have had recent weight gain, elevation of the head of the bed in individuals with nocturnal symptoms, refraining from assuming a supine position after meals and avoidance of meals two to three hours before bedtime. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Lifestyle and dietary modification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3037376203">
         <span class="h3">
          Optimize PPI therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with reflux symptoms despite standard dose once daily PPI (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         40 mg once daily), options include splitting the dose (eg, omeprazole 20 mg twice daily), doubling the PPI dose (eg, omeprazole 40 mg twice daily), or switching to another PPI (eg,
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         30 mg once daily). When splitting or doubling the PPI dose, PPIs should be administered before breakfast and before dinner. Physiologic studies have also demonstrated improved nocturnal acid breakthrough with split dosing as compared with once daily dosing [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         We usually double the PPI dose for eight weeks before considering an alternative PPI. In one study, doubling the PPI dose in patients with symptomatic GERD, despite once daily PPI therapy, increased the rate of overall symptom improvement by 22 to 26 percent [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
         However, both options appear to be effective in controlling heartburn [
         <a href="#rid39">
          39,41
         </a>
         ]. In a randomized trial, 328 patients with persistent GERD symptoms on treatment with single dose
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         were assigned to twice daily lansoprazole or single dose
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         for eight weeks. At the end of treatment, there was no significant difference in the number of heartburn-free days between the two groups. Some experts have suggested splitting the doses to provide double dose PPI four times daily (eg,
         <a class="drug drug_general" data-topicid="9519" href="/z/d/drug information/9519.html" rel="external">
          rabeprazole
         </a>
         10 mg four times daily). However, evidence to support this strategy is limited to a physiologic study which demonstrated greater reduction in intragastric pH over 24 hours as compared with once or twice daily dosing [
         <a href="#rid42">
          42
         </a>
         ]. Data to support a further escalation in PPI dose are lacking.
        </p>
        <p class="headingAnchor" id="H3417117953">
         <span class="h2">
          Diagnostic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic testing in patients with GERD usually consists of an upper endoscopy and esophageal impedance pH testing. Additional evaluation should be pursued based on the type of ongoing symptoms (eg, esophageal manometry in patients with regurgitation, gastric emptying study in patients with vomiting).
        </p>
        <p class="headingAnchor" id="H2369242136">
         <span class="h3">
          Upper endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients who fail PPI therapy, we perform an upper endoscopy with biopsies of the esophagus, if not performed in the last one year. Upper endoscopy can rule out alternative diagnoses (eg, eosinophilic esophagitis, infection and pill injury, achalasia). However, adequate biopsies of the esophagus are needed to rule out eosinophilic esophagitis (two to four biopsies from the distal esophagus and two to four from the mid or proximal esophagus). (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Histology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Esophageal impedance pH testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who fail twice daily PPI therapy should also undergo esophageal pH monitoring. Esophageal pH monitoring with impedance is preferred to wireless pH capsule and the traditional pH probe, as it has the advantage of detection of non-acid in addition to acid reflux [
         <a href="#rid43">
          43,44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2248.html" rel="external">
          "Esophageal multichannel intraluminal impedance testing"
         </a>
         .)
        </p>
        <p>
         Impedance pH testing can be performed while off PPI therapy in patients without typical GERD symptoms to determine if gastroesophageal reflux is the cause of their symptoms. Testing should be performed while on PPI treatment in patients with a partial response to PPIs to determine if there is continued pathological acid or non-acid exposure despite acid suppressive therapy [
         <a href="#rid45">
          45
         </a>
         ]. It can also help predict which patients have acid reflux off PPI therapy [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2248.html" rel="external">
          "Esophageal multichannel intraluminal impedance testing", section on 'Testing on or off proton pump inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1992771420">
         <span class="h3">
          Esophageal manometry
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform esophageal manometry in patients with dysphagia and regurgitation and prior to invasive antireflux therapies to exclude an esophageal motility disorder [
         <a href="#rid45">
          45,47,48
         </a>
         ]. GERD can be distinguished from rumination syndrome by impedance pH manometry by detecting gastric straining preceding or during reflux events that extend to the proximal esophagus. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Esophageal manometry'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2238.html" rel="external">
          "Overview of gastrointestinal motility testing", section on 'Esophageal manometry'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1992771471">
         <span class="h1">
          SUBSEQUENT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subsequent management in patients who have undergone esophageal pH testing are based on the pH of the refluxate. If pH testing cannot be performed, empiric management is based on the type of ongoing symptoms. (See
         <a class="local">
          'Patients with impedance-pH results'
         </a>
         below and
         <a class="local">
          'Patients without impedance pH testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3568282545">
         <span class="h2">
          Patients with impedance-pH results
         </span>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Residual acid reflux
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alginates
         </strong>
         – In patients with refractory heartburn, who demonstrate acid reflux on esophageal pH testing while on a twice daily PPI, we use concurrent sodium alginate, if available. Alginates can potentially buffer the acid pocket in the most proximal gastric cardia and form a viscous raft at the gastroesophageal junction. However, the efficacy of sodium alginate in patients with refractory GERD has not been demonstrated and its availability is limited. (See
         <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">
          "Pathophysiology of reflux esophagitis", section on 'Impaired esophageal emptying'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          H2 receptor antagonists
         </strong>
         – In patients with persistent acid reflux symptoms despite PPI therapy (with or without alginates), we add a bedtime histamine 2 receptor antagonist (H2RA) [
         <a href="#rid49">
          49
         </a>
         ]. Tolerance develops rapidly in patients on H2RAs and can develop after one week of therapy [
         <a href="#rid50">
          50-53
         </a>
         ]. If clinical tolerance develops, H2RA can be used intermittently or on demand [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Surface agents and alginates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reflux inhibitors
         </strong>
         – We use
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         as adjunctive treatment in patients with persistent symptoms despite a PPI with a H2RA. We initiate baclofen at a low dose (5 to 10 mg twice a day before meals). In patients who fail to respond, we make incremental changes and increase the dose by 5 mg every four days to 20 mg three times a day while carefully monitoring for side effects. Because baclofen crosses the blood-brain barrier, a variety of central nervous system-related side effects may occur. These include somnolence, confusion, dizziness, lightheadedness, drowsiness, weakness, and trembling. We usually continue baclofen for four to eight weeks before stopping if it is ineffective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data to support the use of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         in patients with refractory GERD have several limitations. In a meta-analysis of nine randomized trials that included 283 patients with GERD and healthy volunteers who were assigned to baclofen or placebo, baclofen resulted in a reduction in the number of reflux episodes per patient, the average length of reflux episodes, and the incidence of transient lower esophageal sphincter relaxation [
         <a href="#rid55">
          55
         </a>
         ]. However, only one trial included in the meta-analysis evaluated baclofen as an add-on therapy to PPIs. Other limitations included short duration of follow-up (range 12 hours to four weeks) and the inclusion of patients with ongoing non-acid reflux. (See
         <a class="medical medical_review" href="/z/d/html/2244.html" rel="external">
          "Non-acid reflux: Clinical manifestations, diagnosis, and management", section on 'Reflux inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-reflux procedures
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-reflux surgery
         </strong>
         – Antireflux surgery is reserved for patients who require high doses of PPIs to control symptoms, for persistent proven GERD symptoms or esophageal mucosal damage despite maximal medical therapy, and when there is significant structural disruption at the esophagogastric junction (eg, hiatus hernia). Surgery is not recommended in patients who demonstrate a complete lack of response to PPI therapy [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">
          "Surgical treatment of gastroesophageal reflux in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Endoscopic procedures
         </strong>
         – The two main endoscopic approaches for treating GERD include application of controlled radiofrequency energy to the lower esophageal sphincter region (Stretta procedure) and transoral incisionless fundoplication [
         <a href="#rid56">
          56
         </a>
         ]. Both techniques have demonstrated a decrease in PPI requirement in patients with GERD. However, their long-term efficacy has not been established. (See
         <a class="medical medical_review" href="/z/d/html/2254.html" rel="external">
          "Radiofrequency treatment for gastroesophageal reflux disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2616698043">
         <span class="h3">
          Reflux hypersensitivity or functional heartburn
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be reassured regarding the benign nature of these conditions. In patients with functional heartburn or reflux hypersensitivity, we suggest a trial of pain modulators (eg, tricyclic antidepressant, selective serotonin uptake inhibitor, serotonin-norepinephrine reuptake inhibitors, or
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         ). We usually begin with
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         25 mg,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         20 mg, or
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         20 mg. The initial dose should be adjusted based upon tolerance and response. Due to the delayed onset of action of antidepressants, two to four weeks of therapy should be attempted before increasing the dose. We usually continue treatment for 12 weeks before stopping if it is ineffective.
        </p>
        <p>
        </p>
        <p>
         The decision to continue PPI therapy in patients with reflux hypersensitivity or functional heartburn is based on the patients response to PPI therapy (partial response or no response), and whether pH testing was performed on PPI therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with reflux hypersensitivity or functional heartburn who have had a partial response to PPI therapy (or in whom pH testing was performed on PPI therapy), pain modulators are used in addition to PPI therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients reflux hypersensitivity or functional heartburn without a symptomatic response to PPI therapy (or in whom pH testing was performed off PPI therapy), we discontinue PPI therapy and use pain modulators alone.
        </p>
        <p>
        </p>
        <p>
         Pain modulators have been shown to improve esophageal pain in patients with other functional esophageal disorders such as functional chest pain of esophageal origin. However, evidence of their efficacy in patients with reflux hypersensitivity and functional heartburn are limited given the lack of randomized trials [
         <a href="#rid57">
          57-60
         </a>
         ]. In a randomized trial that included 252 patients who underwent pH impedance testing, 75 patients with reflux hypersensitivity were assigned to receive
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         or placebo [
         <a href="#rid60">
          60
         </a>
         ]. At six months, patients treated with citalopram were significantly less likely to report reflux symptoms (39 versus 67 percent).
        </p>
        <p class="headingAnchor" id="H2534372992">
         <span class="h3">
          Non-acid reflux
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with refractory GERD who demonstrate symptoms associated with non-acid reflux, we suggest a trial of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         . The diagnosis and management of patients with non-acid reflux is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2244.html" rel="external">
          "Non-acid reflux: Clinical manifestations, diagnosis, and management", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35407952">
         <span class="h2">
          Patients without impedance pH testing
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients whose symptoms are primarily regurgitation, we use an empiric trial of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         . (See
         <a class="local">
          'Residual acid reflux'
         </a>
         above and
         <a class="local">
          'Non-acid reflux'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who primarily report heartburn, we generally begin with a trial of an H2 receptor antagonist (H2RA) at bedtime but advise that it be used intermittently to avoid tachyphylaxis. We reserve a trial of pain modulators (eg,
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ) for patients who fail to respond to the addition of H2RAs. (See
         <a class="local">
          'Reflux hypersensitivity or functional heartburn'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2264487032">
         <span class="h2">
          Other therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prokinetics in patients with delayed gastric emptying
         </strong>
         – Prokinetic agents (eg,
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         ) are reserved for patients with refractory GERD and objective evidence of delayed gastric emptying on diagnostic testing. (See
         <a class="medical medical_review" href="/z/d/html/2640.html" rel="external">
          "Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Assess gastric motility'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis of 12 randomized trials that included 2403 patients with GERD demonstrated modest reductions in symptom scores when prokinetics were added to PPI therapy [
         <a href="#rid61">
          61
         </a>
         ]. The combination did not increase healing of erosive esophagitis or improve esophageal motor performance, but patients treated with prokinetics were significantly more likely to experience adverse effects. (See
         <a class="medical medical_review" href="/z/d/html/2640.html" rel="external">
          "Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Assess gastric motility'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">
          "Treatment of gastroparesis", section on 'Prokinetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bile acid binders
         </strong>
         – Bile acid binders may have a role in the treatment of refractory GERD when used in combination with PPI therapy or as stand-alone therapy, however, further studies are needed [
         <a href="#rid11">
          11,62
         </a>
         ]. In a randomized trial in which 280 patients with refractory GERD symptoms despite once-daily PPI therapy were assigned to receive an investigational gastric retentive, extended release
         <a class="drug drug_general" data-topicid="8954" href="/z/d/drug information/8954.html" rel="external">
          colesevelam
         </a>
         formulation (IW-3718; 500 mg, 1000 mg, or 1500 mg twice daily) or placebo, IW-3718 (1500 mg twice daily) significantly reduced heartburn (53 versus 37 percent) and regurgitation (46 versus 34 percent) [
         <a href="#rid11">
          11
         </a>
         ]. Constipation was the most frequent adverse effect. (See
         <a class="local">
          'Alternative diagnoses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acupuncture
         </strong>
         – Acupuncture has been evaluated in patients with GERD who failed PPI once daily [
         <a href="#rid63">
          63
         </a>
         ]. In a small randomized trial 30 patients with classic heartburn refractory to once daily PPI were assigned to doubling the PPI dose (standard of care) or adding acupuncture to their PPI for four weeks. As compared with baseline, the acupuncture group had significant improvement in regurgitation and heartburn. While the potential benefit may be related to treatment of visceral pain, additional studies are needed to define the role of acupuncture in patients with refractory GERD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1989051522">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116050.html" rel="external">
          "Society guideline links: Gastroesophageal reflux in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118166.html" rel="external">
          "Society guideline links: Esophageal manometry and pH testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H427217203">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15325.html" rel="external">
          "Patient education: Acid reflux and GERD in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2011.html" rel="external">
          "Patient education: Gastroesophageal reflux disease in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Approximately 10 and 40 percent of patients with gastroesophageal reflux disease (GERD) fail to respond symptomatically, either partially or completely, to a standard dose of proton pump inhibitors (PPIs). Continued symptoms of GERD despite PPI therapy may be due to insufficient acid suppression, reflux hypersensitivity, functional heartburn, or an alternative etiology. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial assessment and alarm features
         </strong>
         – Patients with continued symptoms should be carefully reassessed, paying specific attention to the compliance and timing of PPI therapy, type of ongoing symptoms and the presence of alarm features that may be suggestive of a gastrointestinal malignancy. Alarm features include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         New onset dyspepsia in patient ≥60 years
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence of gastrointestinal bleeding (hematemesis, melena, hematochezia, occult blood in stool)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Iron deficiency anemia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anorexia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained weight loss
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dysphagia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Odynophagia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent vomiting
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastrointestinal cancer in a first-degree relative
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <strong>
          Diagnostic evaluation and initial management
         </strong>
         – The timing and extent of diagnostic evaluation in a patient with refractory GERD is based on the type of ongoing symptoms and the presence of alarm features  (
         <a class="graphic graphic_algorithm graphicRef70106" href="/z/d/graphic/70106.html" rel="external">
          algorithm 1
         </a>
         ).
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120419">
          (Related Pathway(s):
          <a class="utd-content-120419" href="/pathway/120419?topicRef=2239&amp;source=see_link">
           Gastroesophageal reflux disease: Identification of adults who require upper endoscopy
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with alarm features
         </strong>
         – We perform early upper endoscopy. Patients with alarm features in whom the early upper endoscopy is negative are subsequently managed similarly to patients without alarm features  (
         <a class="graphic graphic_algorithm graphicRef70106" href="/z/d/graphic/70106.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Patients with alarm features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without alarm features
         </strong>
         – Initial management consists of reinforcement of lifestyle modification and compliance with PPI therapy. In patients with persistent symptoms despite once daily PPI therapy, we suggest twice daily PPI therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Switching to a different PPI may be an equally effective alternative. In all patients who fail twice daily PPI therapy, we perform an upper endoscopy with biopsies of the esophagus, if not performed in the last one year. (See
         <a class="local">
          'Residual acid reflux'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional measures based on esophageal pH testing/symptoms
         </strong>
         – Subsequent management in patients who have undergone esophageal pH testing are based on the pH of the refluxate. If pH testing cannot be performed, empiric management is based on the type of ongoing symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with persistent acid reflux on esophageal impedance pH testing or when testing is unavailable and patients primarily report heartburn, we suggest adding a bedtime H2RA (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If clinical tolerance develops, H2RA can be used intermittently or on demand. (See
         <a class="local">
          'Residual acid reflux'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with symptoms associated with non-acidic reflux on an esophageal impedance pH study or when testing is unavailable and patients primarily report regurgitation, we suggest a trial of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Non-acid reflux'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2244.html" rel="external">
          "Non-acid reflux: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with refractory GERD who have a normal esophageal impedance and pH study (esophageal hypersensitivity or functional heartburn), we suggest a trial of visceral analgesics (pain modulators), such as a tricyclic antidepressant, serotonin-norepinephrine reuptake inhibitor, selective serotonin uptake inhibitor, or
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Reflux hypersensitivity or functional heartburn'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with persistent GERD symptoms despite PPI therapy and delayed gastric emptying, we suggest treatment with prokinetics (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Other therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study. J Clin Outcomes Manag 2000; 7:29.
          </a>
         </li>
         <li class="breakAll">
          The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol 2012; 27 Suppl 3:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003; 63:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol 2014; 109:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilder-Smith C, Röhss K, Bokelund Singh S, et al. The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. Aliment Pharmacol Ther 2010; 32:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53:2387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2014; 12:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol 2008; 103:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012; 47:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdallah J, George N, Yamasaki T, et al. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders. Clin Gastroenterol Hepatol 2019; 17:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology 2016; 150:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functional heartburn:  clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013; 25:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006; 101:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008; 53:2621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community. Neurogastroenterol Motil 2014; 26:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus". Gut 1997; 40:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017; 29:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology 2018; 154:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group. Neurogastroenterol Motil 2017; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009; :CD004275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract 2014; 2014:307805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol 2009; 25:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2015; 13:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2010; 105:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SW, Lee H, Lee HJ, et al. Low-dose amitriptyline combined with proton pump inhibitor for functional chest pain. World J Gastroenterol 2013; 19:4958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20:2412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology 2020; 158:2093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2239 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17661525" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22684483" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22486864" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Therapeutic options for refractory gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20662774" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15290657" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effectiveness of proton pump inhibitors in nonerosive reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12656653" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Barrett's oesophagus: optimal strategies for prevention and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18625135" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Refractory GERD: what is it?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10562747" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Factors influencing compliance in long-term proton pump inhibitor therapy in general practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16011666" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24896751" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16669962" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20955444" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16556669" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18356117" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16187196" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18322797" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11467629" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The role of acid and duodenal gastroesophageal reflux in symptomatic GERD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667483" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The role of esophageal pH monitoring in symptomatic patients on PPI therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24184737" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19491829" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18445095" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Characteristics of symptomatic reflux episodes on Acid suppressive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22038553" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29913281" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27144625" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Functional Esophageal Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23128061" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Functional heartburn:  clinical characteristics and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15712642" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16573776" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256933" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7672684" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18194508" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17635379" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19035971" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Review article: gastro-oesophageal reflux disease and psychological comorbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24916517" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15180713" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9178669" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9882032" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11121907" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9203934" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16431305" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22882464" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28370768" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16271338" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23419381" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Guidelines for the diagnosis and management of gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19281866" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28827081" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Management of Gastroesophageal Reflux Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28544357" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9834259" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11874994" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17944740" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12650785" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821323" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16336606" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25389436" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19342950" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : What is left of the endoscopic antireflux devices?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24997325" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20332772" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23946601" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Low-dose amitriptyline combined with proton pump inhibitor for functional chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21625270" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24605040" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32092310" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17875198" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
